BRCA1 and ovarian carcinoma: This translates to a reduction in ovarian cancer-specific mortality between 80–96% and in breast cancer-specific mortality of 42%, which is more pronounced for BRCA1 (HR 0.45, p < 0.0001) vs. BRCA2 mutation carriers for whom the reduction loses significance (HR 0.88, p = 0.75) [22].